Charleston Laboratories, Inc. is involved in developing treatments for acute pain and associated symptoms such as opioid-induced nausea and vomiting. Self-described as focusing on innovative therapeutics.

Charleston Laboratories, Inc.

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Metric
Company Name	Charleston Laboratories, Inc.	Corcept Therapeutics Inc.
Symbol		CORT
MSH ID	COM:CHARLESTONLABS	COM:CORCEPT
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Biotechnology
Country	US	US
Stage
Employee Count		352
Website	charlestonlabs.com	corcept.com
LinkedIn
Founders

Metric
Market Cap		6.03B
Enterprise Value
Monthly Web Traffic		53.48K
Web Traffic Growth		3.98
Valuation
Raised Capital

Metric
Revenue		482.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit		475.89M
EBITDA		109.64M
Operating Income		107.28M
Net Income		106.14M
EPS		1.02
Diluted EPS		0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.99
Operating Profit Margin		0.23
EBITDA Margin		0.23
Net Profit Margin		0.23
Return on Equity		0.24
Return on Assets		0.18
Return on Capital Employed		0.22

CHAR

COM:CHARLESTONLABS

Charleston Laboratories, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		24.15
P/B Ratio		4.78
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		9.13
EV Multiple		41.21

Metric
Days Sales Outstanding		39.44
Days Payables Outstanding		1.00K
Days Inventory Outstanding		435.27
Operating Cycle		476.98
Cash Conversion Cycle		-212.43
Asset Turnover		0.80

Metric
Operating Cash Flow		127.04M
Free Cash Flow		126.90M
Cash Flow to Debt		1.64K
Operating Cash Flow/Sales		0.26
Free Cash Flow Yield		0.07

Metric
Cash & Equivalents		135.55M
Accounts Receivable		-10.07M
Inventory		7.73M
Goodwill
Debt to Capitalization		0.01
Debt to Assets		0.00
Current Ratio		3.54
Quick Ratio		5.48

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.10
R&D to Revenue		0.37
SG&A to Revenue